
|Videos|September 8, 2016
Jeffrey Weber on the Role of Oncology Nurses in Treating Patients With Checkpoint Inhibitors
Author(s)Jeffrey Weber, MD, PhD
Jeffrey Weber, MD, PhD, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, discusses the role of the oncology nurse when treating patients who have cancer with checkpoint inhibitors.
Advertisement
Jeffrey Weber, MD, PhD, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, discusses the role of the oncology nurse when treating patients who have cancer with checkpoint inhibitors.
Nurses are typically the “first line of defense,” Weber said, as they are often are the first ones to hear about how patients are feeling; thus, it is crucial for oncology nurses to know what to look for regarding adverse events when treating patients who are on checkpoint inhibitors.
Advertisement
Related Content
Advertisement




First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:

Latest CME
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
2
Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses
3
Addressing Financial Toxicity: Team-Based Workflows in Oncology Care
4
ASCO Releases First Living Guideline for Recurrent Ovarian Cancer Care
5












































